MedTrace Logo

Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy

NCT01726816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2017-05-03

No results posted yet for this study

Summary

This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial.

* Screening period (4 week)
* Double blind treatment period (16 weeks)

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Probucol 250mg/day

Probucol 250mg + Placebo

DRUG

Probucol 500mg/day

Probucol 500mg + Placebo

DRUG

Placebo

Probucol matching placebo

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • MoonKyu Lee, professor · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-04-30
Completion
2014-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726816 on ClinicalTrials.gov